Holen Sie sich die Stockscreener-App
91.85
0.04%
-0.04
Handel nachbörslich:
92.19
0.34
+0.37%
Schlusskurs vom Vortag:
$91.89
Offen:
$91.58
24-Stunden-Volumen:
265.59K
Relative Volume:
0.49
Marktkapitalisierung:
$907.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.66%
1M Leistung:
+3.12%
6M Leistung:
+10.29%
1J Leistung:
-2.88%
1-Tages-Spanne:
$91.17
$92.01
1-Wochen-Bereich:
$91.17
$94.09
52-Wochen-Spanne:
$77.67
$95.27
Vaneck Pharmaceutical Etf Stock (PPH) Company Profile
Firmenname
Vaneck Pharmaceutical Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PPH
Vaneck Pharmaceutical Etf
|
91.85 | 907.13M | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
326.83 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
662.23 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
665.48 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
255.61 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
598.00 | 124.43B | 0 | 0 | 0 | 0.00 |
Vaneck Pharmaceutical Etf Aktie (PPH) Neueste Nachrichten
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? - AOL.com
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? - MSN
4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio - The Globe and Mail
Pharmaceutical ETF on track for best week since 2020 - MarketWatch
PPH: The Big Pharma ETF (NASDAQ:PPH) - Seeking Alpha
VanEck Pharmaceutical ETF (NASDAQ:PPH) Sees Unusually-High Trading Volume Following Dividend Announcement - Defense World
Headlines Boost Pharma Stocks. Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Speak to Rally Into Year End - MSN
Headlines Boost Pharma Stocks. What the Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Say - Barron's
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk - inkl
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms - Benzinga
Big Pharma rebounds despite Trump’s latest tariff threat - Seeking Alpha
Biopharma Stocks Rally After Trump Threatens 100% Pharmaceuticals Tariff - inkl
President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio - Seeking Alpha
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit - The Globe and Mail
PPH: Excellent Pharmaceutical ETF, But Bad Timing To Invest (NASDAQ:PPH) - Seeking Alpha
How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse - Seeking Alpha
Belpointe Asset Management LLC Takes $528,000 Position in VanEck Pharmaceutical ETF $PPH - Defense World
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now? - sharewise.com
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing - Benzinga
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? - sharewise.com
Pharma stocks higher as Trump backs down from 250% tariff threat - Seeking Alpha
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain - The Globe and Mail
LPL Financial LLC Cuts Position in VanEck Pharmaceutical ETF (NASDAQ:PPH) - Defense World
4. SPDR S&P Pharmaceuticals ETF (ARCA:XPH) - Investing News Network
Pharma ETFs: Your Key to Diversification in the Pharmaceutical Sector - Investing News Network
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data - The Globe and Mail
Markets Shrug as Chip and Pharma Stocks Navigate Trump's New Tariff Blitz - Money Morning
Envestnet Asset Management Inc. Reduces Stock Holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH) - Defense World
Cetera Investment Advisers Has $3.16 Million Stake in VanEck Pharmaceutical ETF (NASDAQ:PPH) - Defense World
Novo Nordisk Shares Plunge, Drag Down Weight-Loss-Drug ETFs - ETF.com
J&J leads big pharma higher after earnings despite Trump’s latest tariff threat - MSN
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook - MSN
ETFs To Gain On JNJ's Solid Q1 Earnings & Upbeat Outlook - Barchart.com
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' - Benzinga
Short bets against S&P 500 healthcare stocks climb in June; MRNA tops list again - Seeking Alpha
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies - Benzinga
Finanzdaten der Vaneck Pharmaceutical Etf-Aktie (PPH)
Es liegen keine Finanzdaten für Vaneck Pharmaceutical Etf (PPH) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):